Clinical trial · Observational
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
NCT03878537CI-TRIAL-00050851unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression Free Survival
- timeFrame
- 24 months
- description
- Cell free tumor DNA based PFS
- measure
- Progression Free Survival
- timeFrame
- 24 months
- description
- Clinical or radiographic based PFS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC * Baseline CT imaging available Exclusion Criteria: * Patients unable to undergo biopsy for initial tissue diagnosis * Patients who do not wish to pursue standard of care therapy * Patients with another diagnosis of malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.